跳至主要内容
临床试验/EUCTR2015-005681-37-BE
EUCTR2015-005681-37-BE
进行中(未招募)
1 期

Evaluation of the evolution of imaging markers of cartilage degradation in patients with knee osteoarthritis receiving DROGLICAN®: a Pilot Study - DRIP

BIOIBERICA S.A.0 个研究点目标入组 20 人2016年2月25日

概览

阶段
1 期
干预措施
未指定
疾病 / 适应症
Knee Osteoarthritis
发起方
BIOIBERICA S.A.
入组人数
20
状态
进行中(未招募)
最后更新
7年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2016年2月25日
结束日期
待定
最后更新
7年前
研究类型
Interventional clinical trial of medicinal product

研究者

发起方
BIOIBERICA S.A.

入排标准

入选标准

  • Male or female \= 40 years of age with BMI \= 40
  • Femorotibial knee OA (Uni\- or bilateral)
  • o Responding to clinical and radiological criteria of American College of Rheumatology (ACR)
  • o Symptomatic for more than 6 months in the most painful knee
  • o Radiological K\&L grade II\-III in radiographs from less than 12 months
  • Moderate\-to\-severe knee pain: knee pain score evaluated on VAS (0\-100\) \= 40 over the last 24 hours at the inclusion visit (the most painful knee is considered)
  • Able to follow the instructions of the study
  • Having signed an informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

排除标准

  • Related to the OA pathology
  • Recent trauma (\< 1 month) of the knee responsible of the symptomatic knee
  • Concurrent articular disease interfering with the evaluation of OA and/or pain such as articular dysplasia, aspectic osteonecrosis, acromegaly, Paget’s disease, hemophilia, hemochromatosis, chondromatosis, villonodular synovitis of the knee, seronegative spondyloarthropathy, rheumatoid arthritis, gouty arthritis , infectious arthritis, radiculalgia in the lower limbs, arteritis, etc.
  • Radiological K\&L grade I or IV
  • Prosthesis in the target knee
  • Related to treatments
  • Analgesics to manage OA knee pain (Paracetamol, oral NSAIDs, etc.) 24h before inclusion and any follow\-up visits
  • Corticosteroids injection in the target knee in the month preceding inclusion
  • Hyaluronan injection in the target knee in the last 6 months
  • Oral corticotherapy \= 5mg/day in the last 3 months

结局指标

主要结局

未指定

相似试验

进行中(未招募)
1 期
Amyloid imaging in Alzheimer’s disease, frontotemporal dementia and healthy volunteersse of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.MedDRA version: 14.0 Level: PT Classification code 10061816 Term: Diagnostic procedure System Organ Class: 10022891 - Investigations
EUCTR2008-003597-18-GBAvid Radiopharmaceuticals, Inc34
已完成
2 期
Amyloid imaging in Alzheimer's disease, frontotemporal dementia and healthy volunteersFrontotemporal dementia and Alzheimer's diseaseNervous System DiseasesAlzheimer's disease
ISRCTN58435532Avid Radiopharmaceuticals Inc.40
招募中
不适用
A non-randomised study investigating the use and timing of multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) to develop imaging biomarkers that will be used to predict treatment response following radiotherapy for prostate cancer treatment.
ACTRN12618001810202niversity of Sydney30
招募中
不适用
Analysis of imaging biomarkers in development and growth of geographic atrophy in Japanese with dry aged macular degeneratiodry age-related macular degeneration
JPRN-UMIN000050605Jichi Medical University40
招募中
不适用
Evaluation of imaging biomarkers and longitudinal assessment of global and regional cardiac function by cardiac MRI during recovery from COVID-19 infection in a multicenter normalized cohortZ03.8Observation for other suspected diseases and conditions
DRKS00028901Klinikum der Universität München, Campus Großhadern150